Liminatus Pharma, Inc. Class A Common Stock (LIMN) - Net Assets
Based on the latest financial reports, Liminatus Pharma, Inc. Class A Common Stock (LIMN) has net assets worth $-9.81 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($512.79K) and total liabilities ($10.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check LIMN tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-9.81 Million |
| % of Total Assets | -1913.96% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 413.36 |
Liminatus Pharma, Inc. Class A Common Stock - Net Assets Trend (2021–2025)
This chart illustrates how Liminatus Pharma, Inc. Class A Common Stock's net assets have evolved over time, based on quarterly financial data. See LIMN defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Liminatus Pharma, Inc. Class A Common Stock (2021–2025)
The table below shows the annual net assets of Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2025. For live valuation and market cap data, see market cap of Liminatus Pharma, Inc. Class A Common St.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-9.81 Million | +38.16% |
| 2024-12-31 | $-15.87 Million | -48.42% |
| 2023-12-31 | $-10.69 Million | -926.20% |
| 2022-12-31 | $1.29 Million | -99.49% |
| 2021-12-31 | $254.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Liminatus Pharma, Inc. Class A Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1773990800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.71K | % |
| Other Components | $29.05 Million | % |
| Total Equity | $-9.81 Million | 100.00% |
Liminatus Pharma, Inc. Class A Common Stock Competitors by Market Cap
The table below lists competitors of Liminatus Pharma, Inc. Class A Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pulmatrix Inc
NASDAQ:PULM
|
$5.48 Million |
|
Philly Shipyard ASA
OL:PHLY
|
$5.48 Million |
|
Siamraj Public Company Limited
BK:SR
|
$5.48 Million |
|
Alefarm Brewing AS
CO:ALEFRM
|
$5.49 Million |
|
Enova Mining Ltd
AU:ENV
|
$5.47 Million |
|
Compodium International AB
ST:COMPDM
|
$5.46 Million |
|
Narryer Metals Ltd
AU:NYM
|
$5.46 Million |
|
First Venture Sweden AB Series B
ST:FIRST-B
|
$5.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Liminatus Pharma, Inc. Class A Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -15,869,899 to -9,814,690, a change of 6,055,209.
- Net loss of 10,206,517 reduced equity.
- New share issuances of 10,556,500 increased equity.
- Other comprehensive income increased equity by 160,677.
- Other factors increased equity by 5,544,549.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.21 Million | -103.99% |
| Share Issuances | $10.56 Million | +107.56% |
| Other Comprehensive Income | $160.68K | +1.64% |
| Other Changes | $5.54 Million | +56.49% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Liminatus Pharma, Inc. Class A Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $7.39 | $0.12 | x |
| 2022-12-31 | $0.04 | $0.12 | x |
| 2023-12-31 | $-1.33 | $0.12 | x |
| 2024-12-31 | $-2.21 | $0.12 | x |
| 2025-12-31 | $-0.41 | $0.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Liminatus Pharma, Inc. Class A Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-44.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 1.71% | 0.00% | 0.00x | 1.08x | $-21.12 Million |
| 2022 | -226.24% | 0.00% | 0.00x | 11.97x | $-3.06 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-156.94K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.32 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.23 Million |
Industry Comparison
This section compares Liminatus Pharma, Inc. Class A Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $-9.81 Million | 1.71% | N/A | $5.48 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.